Alzamend Neuro
Alzamend Neuro
ALZN
NASDAQ
0.68
USD
1.49%
About
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002.
AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment.
ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 9.8M |
| Three Month Average Volume | 33.1M |
| High Low | |
| Fifty-Two Week High | 44.79 USD |
| Fifty-Two Week Low | 1.835 USD |
| Fifty-Two Week High Date | 05 Sep 2023 |
| Fifty-Two Week Low Date | 13 Aug 2024 |
| Price and Volume | |
| Current Price | 2.35 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -31.77% |
| Thirteen Week Relative Price Change | -62.78% |
| Twenty-Six Week Relative Price Change | -76.72% |
| Fifty-Two Week Relative Price Change | -95.23% |
| Year-to-Date Relative Price Change | -77.70% |
| Price Change | |
| One Day Price Change | 2.62% |
| Thirteen Week Price Change | -60.17% |
| Twenty-Six Week Price Change | -74.40% |
| Five Day Price Change | -23.70% |
| Fifty-Two Week Price Change | -94.02% |
| Year-to-Date Price Change | -73.60% |
| Month-to-Date Price Change | -34.17% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -3.77062 USD |
| Book Value Per Share (Most Recent Quarter) | -3.77062 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -3.77062 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -3.77062 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -14.61319 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -14.70331 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -14.81413 USD |
| Normalized (Last Fiscal Year) | -14.70331 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -14.70331 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -14.81413 USD |
| Including Extraordinary Items (Last Fiscal Year) | -14.70331 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -14.81413 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.54658 USD |
| Cash Per Share (Most Recent Quarter) | 0.54658 USD |
| Cash Flow Per Share (Last Fiscal Year) | -14.62821 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -14.62813 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -12.44099 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 75.85% |
| EPS Change (Trailing Twelve Months) | 35.19% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -75,340 |
| Net Debt (Last Fiscal Year) | -75,340 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 0 |
| Current Ratio (Most Recent Quarter) | 0 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -8,417,230 |
| Free Cash Flow (Trailing Twelve Months) | -8,417,230 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -984 |
| Net Interest Coverage (Trailing Twelve Months) | -983 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -303.88% |
| Return on Assets (Trailing Twelve Months) | -303.88% |
| Return on Assets (5 Year) | -177.86% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -4,408.39% |
| Return on Equity (Trailing Twelve Months) | -4,408.39% |
| Return on Equity (5 Year) | -257.81% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -4,408.39% |
| Return on Investment (Trailing Twelve Months) | -4,408.39% |
| Return on Investment (5 Year) | -257.81% |